- Home
- KO vs NVO Comparison
KO vs NVO Comparison
Compare KO & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KO
- NVO
- Stock Information
- Founded
- KO 1886
- NVO 1923
- Country
- KO United States
- NVO Denmark
- Employees
- KO N/A
- NVO N/A
- Industry
- KO Beverages (Production/Distribution)
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KO Consumer Staples
- NVO Health Care
- Exchange
- KO Nasdaq
- NVO Nasdaq
- Market Cap
- KO 286.8B
- NVO 243.4B
- IPO Year
- KO 1919
- NVO N/A
- Fundamental
- Price
- KO $68.62
- NVO $49.89
- Analyst Decision
- KO Strong Buy
- NVO Buy
- Analyst Count
- KO 12
- NVO 10
- Target Price
- KO $78.00
- NVO $80.40
- AVG Volume (30 Days)
- KO 15.7M
- NVO 10.6M
- Earning Date
- KO 10-21-2025
- NVO 11-05-2025
- Dividend Yield
- KO 2.98%
- NVO 2.40%
- EPS Growth
- KO 25.34
- NVO 24.25
- EPS
- KO 3.02
- NVO 3.93
- Revenue
- KO $47,663,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- KO $5.92
- NVO $9.58
- Revenue Next Year
- KO $5.53
- NVO $7.39
- P/E Ratio
- KO $22.63
- NVO $13.08
- Revenue Growth
- KO 2.80
- NVO 20.91
- 52 Week Low
- KO $60.62
- NVO $45.05
- 52 Week High
- KO $74.38
- NVO $113.76
- Technical
- Relative Strength Index (RSI)
- KO 51.79
- NVO 28.27
- Support Level
- KO $68.16
- NVO $52.38
- Resistance Level
- KO $70.90
- NVO $53.55
- Average True Range (ATR)
- KO 0.90
- NVO 0.99
- MACD
- KO 0.07
- NVO -0.60
- Stochastic Oscillator
- KO 46.66
- NVO 5.24
About KO Coca-Cola Company (The)
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.